【24h】

SFLT1 in preeclampsia: Trophoblast defense against a decidual VEGFA barrage?

机译:子痫前期的 SFLT1:滋养层防御蜕膜 VEGFA 弹幕?

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Preeclampsia, a life-threatening complication of human pregnancy, has a spectrum of clinical signs and is likely caused by an array of pathological mechanisms. However, elevated levels of soluble fms-like tyrosine kinase-1 (sFLT1) in the placenta and in the maternal circulation has emerged as a common finding in women with preeclampsia and likely is a causative factor in this disorder. In this issue of the JCI, Fan and colleagues provide experimental evidence from both humans and mice that suggests placental trophoblast cells overexpress sFLT1 in self defense against excessive VEGFA produced by maternal decidual cells. The authors' work thus implicates the decidual cells of the mother as the culprit responsible for increased placental expression of sFLT1, a VEGFA antagonist that enters the maternal circulation and consequently induces the clinical signs of preeclampsia.
机译:先兆子痫是人类妊娠中一种危及生命的并发症,具有一系列临床症状,可能由一系列病理机制引起。然而,胎盘和母体循环中可溶性 fms 样酪氨酸激酶-1 (sFLT1) 水平升高已成为子痫前期女性的常见发现,并且可能是该疾病的致病因素。在本期JCI中,Fan及其同事提供了来自人类和小鼠的实验证据,表明胎盘滋养层细胞过度表达sFLT1,以自我防御母体蜕膜细胞产生的过量VEGFA。因此,作者的工作表明,母亲的蜕膜细胞是导致sFLT1胎盘表达增加的罪魁祸首,sFLT1是一种进入母体循环的VEGFA拮抗剂,因此会诱发先兆子痫的临床症状。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号